CORCEPT THERAPEUTICS INC 8K

Corcept Therapeutics reported strong Q2 2026 results, raised 2026 revenue guidance, and updated investors on multiple late-stage clinical and regulatory programs, including Lifyorli’s launch and relacorilant’s resubmitted NDA for Cushing’s syndrome.

On July 29, 2026, Corcept Therapeutics Incorporated reported strong second quarter 2026 financial results, highlighted by a 32% year-over-year increase in revenue to $256.1 million driven by $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli, raised its full-year 2026 revenue guidance to $1.1–$1.2 billion, and provided a broad corporate update on its clinical pipeline, including ongoing commercialization of Lifyorli in platinum-resistant ovarian cancer, resubmission of the NDA for relacorilant in Cushing’s syndrome with a December 17, 2026 PDUFA date, anticipated EMA decision on relacorilant plus nab-paclitaxel, progress in multiple oncology, MASH, and ALS trials, and confirmation of a solid balance sheet with $544.6 million in cash and investments at June 30, 2026.

Filing Facts

CIK

1088856

Ticker

CORT

Form

8K

Source Type

fda

Accession

0001628280-26-050607

Alert Tier

7